The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel

Int J Cardiol. 2013 Sep 30;168(2):1594-6. doi: 10.1016/j.ijcard.2013.01.040. Epub 2013 Feb 10.

Authors

Dimitris Tousoulis¹, Gerasimos Siasos, Marina Zaromitidou, Evangelos Oikonomou, Konstantinos Maniatis, Stamatios Kioufis, Eleni Kokkou, Athanasios G Papavassiliou, Christodoulos Stefanadis

Affiliation

¹ 1st Department of Cardiology, 'Hippokration' Hospital, University of Athens Medical School, Athens, Greece. Electronic address: [email protected].

PMID: 23402725
DOI: 10.1016/j.ijcard.2013.01.040

No abstract available

Keywords: Clopidogrel; Coronary artery disease; Platelet function; Polymorphism.

Publication types

Letter

MeSH terms

Aged
Aryl Hydrocarbon Hydroxylases / genetics*
Blood Platelets / drug effects
Blood Platelets / metabolism*
Cardiovascular Diseases / blood
Cardiovascular Diseases / chemically induced
Cardiovascular Diseases / genetics
Clopidogrel
Coronary Artery Disease / blood*
Coronary Artery Disease / drug therapy
Coronary Artery Disease / genetics*
Cytochrome P-450 CYP2C19
Female
Genotype*
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / pharmacokinetics
Platelet Aggregation Inhibitors / therapeutic use
Ticlopidine / adverse effects
Ticlopidine / analogs & derivatives*
Ticlopidine / pharmacokinetics
Ticlopidine / therapeutic use

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Aryl Hydrocarbon Hydroxylases
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Ticlopidine